Welcome to our dedicated page for Sellas Life Sciences Group news (Ticker: SLS), a resource for investors and traders seeking the latest updates and insights on Sellas Life Sciences Group stock.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on developing novel therapies for cancer, with a strong emphasis on acute myeloid leukemia (AML) and other hematologic malignancies. This news page aggregates company announcements, clinical updates, financial disclosures, and collaboration news related to SLS.
Readers can follow developments around SELLAS’ lead product candidate galinpepimut-S (GPS), a WT1-targeted peptide immunotherapy licensed from Memorial Sloan Kettering Cancer Center, which is being evaluated in the pivotal Phase 3 REGAL trial as a potential maintenance therapy in AML after second complete remission. News items include updates on the REGAL trial’s progress, Independent Data Monitoring Committee recommendations, and commentary from investigators and key opinion leaders.
The SLS news feed also covers SLS009 (tambiciclib), SELLAS’ highly selective CDK9 inhibitor. Articles highlight Phase 2 clinical data in relapsed or refractory AML with myelodysplastic syndrome-related changes (AML-MR) after prior venetoclax-based treatment, including reported response rates, survival outcomes, and safety findings for SLS009 in combination with azacitidine and venetoclax. Preclinical results in T-cell prolymphocytic leukemia (T-PLL) and mechanistic studies in AML cell lines are also featured in conference-related releases.
In addition to clinical and scientific news, this page includes corporate updates such as participation in investor conferences, warrant exercise transactions, and quarterly financial results as reported in press releases referenced by Form 8-K filings. Investors and followers of SLS can use this page to review the sequence of material events, from R&D days and conference presentations to financing activities and operational updates, in one organized stream of company-specific news.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) has had its IND application accepted by China’s NMPA to initiate a Phase I trial of 3D189 (GPS) for hematological malignancies, expected to start in mid-2022. This milestone will trigger a payment to SELLAS, with additional payments linked to further trials. GPS has shown encouraging results in prior studies and aims to improve outcomes for cancer patients globally. Collaboration with 3D Medicines may also extend to ongoing Phase III trials in AML, enhancing their combined treatment options.
SELLAS Life Sciences Group (NASDAQ: SLS) has announced the promotion of John T. Burns to Senior Vice President, Finance, and Chief Accounting Officer. Burns, who joined SELLAS in 2013, has played a vital role in the company’s financial strategy and execution. His promotion reflects his contributions to the company’s growth, particularly in advancing its clinical programs for cancer immunotherapies. SELLAS is developing innovative treatments, including galinpepimut-S and nelipepimut-S, targeting various cancer types.
SELLAS Life Sciences Group (NASDAQ: SLS) announced the final approval on November 19, 2021, by the United States District Court for the District of New Jersey regarding the settlement of claims related to its predecessor, Galena Biopharma, Inc.. This settlement resolves derivative actions Keller v. Ashton and Johnson v. Schwartz and mandates the adoption of new policies for future commercialization of clinical candidates. The company's insurer will cover attorney's fees up to $270,000. SELLAS focuses on developing cancer immunotherapies, with its lead product candidate, galinpepimut-S (GPS).
SELLAS Life Sciences Group (NASDAQ: SLS) reported Q3 2021 financial results, including a net loss of $7.1 million and no licensing revenue for the quarter. R&D expenses rose to $4.5 million, significantly up from $2.4 million in Q3 2020, driven by clinical trial activities for the Phase 3 REGAL study of galinpepimut-S (GPS) in AML. The company is also planning a Phase 2/3 study for GPS in post-BMT AML patients. As of September 30, 2021, cash equivalents stood at approximately $26.3 million, indicating ongoing financial support for its clinical initiatives.
SELLAS Life Sciences Group (NASDAQ: SLS), a biopharmaceutical company focused on cancer immunotherapies, announced that CEO Angelos Stergiou will participate in two key conferences. The first is the Laguna Biotech CEO Forum from October 10-12, 2021, in Laguna Beach, CA. The second is the A.G.P./Alliance Global Partners Biotech & Specialty Pharma Conference on October 13, 2021, which will be held virtually. SELLAS aims to advance its immunotherapeutic candidates, galinpepimut-S and nelipepimut-S, targeting various cancer indications.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced preliminary court approval for a settlement related to derivative claims against former executives of its predecessor, Galena Biopharma. The settlement includes a stipulation that mandates the company to implement specific policies concerning future commercialization of its clinical candidates. Furthermore, the company's insurer will cover up to $270,000 in legal fees. A final settlement approval hearing is scheduled for November 19, 2021.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced that CEO Angelos Stergiou will present at the 2021 Cantor Global Healthcare Conference on September 28, 2021, at 4:00 p.m. ET. The company specializes in developing innovative cancer immunotherapies, notably its lead candidate galinpepimut-S (GPS), which targets the WT1 protein in various tumors, and nelipepimut-S (NPS), aimed at early-stage breast cancer patients. For further details about the conference or to arrange meetings, interested parties can contact Cantor representatives or KCSA Strategic Communications.
SELLAS Life Sciences Group (SLS) reported significant clinical updates on Galinpepimut-S (GPS), showcasing its potential in treating malignant pleural mesothelioma and WT1+ advanced ovarian cancer. The company highlighted results from a study showing an overall survival (OS) of 48.5 months for AML patients treated with GPS. Financially, SLS recorded licensing revenue of $1.9 million for Q2 2021, with a cash position of $29.9 million as of June 30, 2021. A virtual investor symposium is scheduled for August 17, 2021, to discuss further insights on GPS and its promising clinical data.
SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company, will host a virtual investor symposium on August 17, 2021, focusing on its lead asset, galinpepimut-S (GPS). The event will detail GPS's clinical program and recent data regarding acute myeloid leukemia (AML) treatment. Notably, Dr. Yair Levy, a leading cancer researcher, will join the management team. GPS targets the WT1 protein in various tumors and has potential for treating hematologic malignancies and solid tumors.
SELLAS Life Sciences Group (NASDAQ: SLS) reported encouraging results from its Phase 1/2 clinical trial of its lead immunotherapy, galinpepimut-S (GPS), combined with pembrolizumab for advanced ovarian cancer. Notably, 100% of patients are alive, and 45.5% continue with the treatment. CD8+ T-cell responses increased by an average of +242%, indicating robust immune activation. The disease control rate was 63.6%, with a median progression-free survival of 11.8 weeks in a challenging patient cohort. These findings suggest potential for GPS as a viable therapy in difficult-to-treat cases.